GET DAILY SIGNALSMannatech (MTEX): Reaching $10 Would Require a +16.8% Move
Key Takeaways
- The $10 central target is a fallback objective drawn from public market discussion and a technical milestone — a retest of the stock's 52-week high — rather than an official analyst consensus, which does not meaningfully exist for Mannatech, Incorporated (MTEX).
- With the shares recently trading near $8.56, reaching $10 would require a gain of roughly 16.8%, a substantial move for this thinly traded micro-cap.
- Published analyst coverage is minimal: MarketBeat reports no consensus price target, while the limited available views — including a $6.00 estimate and a $7.50 target — sit below the current price.
- The strongest supporting factors are an extremely low price-to-sales (P/S) ratio near 0.15x and the company's history of periodic tender offers, which have periodically lifted the stock.
- The biggest risks are several years of declining revenue, persistent net losses, and a 2026 going-concern review that delayed the company's annual filing.
- Investors can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
How the $10 Target Came Into View
Mannatech, Incorporated is a small wellness company that develops and sells nutritional supplements, skin-care and anti-aging products, and weight-management items, primarily through network marketing and e-commerce channels. It is a Nasdaq-listed stock, not an exchange-traded fund, with a market capitalization of only about $16.5 million.
Because credible Wall Street coverage of MTEX is extremely thin, a conventional analyst-consensus target cannot be reliably calculated. MarketBeat lists no consensus price target, and the individual figures that do circulate are mostly below the market: a $6.00 estimate noted by TipRanks and a $7.50 Hold figure referenced in financial media, alongside a "Sell" rating from Weiss Ratings in October 2026. None of these can support a forward-looking target above the current price.
Accordingly, the $10 level used here is a fallback objective rooted in public discussion and technical structure, not an analyst average. It corresponds closely to the stock's 52-week high — around $9.97 — and to the round-number, psychological $10 mark that market commentary has referenced as a plausible upside milestone if positive catalysts materialize. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the shares recently trading near $8.56, a move to $10 implies roughly 16.8% upside — a substantial, though not extreme, move. The path would most likely run through a recovery in revenue and profitability, a successful resolution of the going-concern review, or a corporate action such as another tender offer, which has periodically concentrated buying interest in this illiquid stock.
The backdrop is challenging. Revenue has declined from about $137 million in 2022 to roughly $108 million in 2025, and the company posted a net loss with negative earnings per share (EPS) near -$3.91 over the trailing twelve months. A 2026 delay in the annual Form 10-K filing, tied to an auditor's going-concern review, underscores the balance-sheet uncertainty investors must weigh against the stock's low valuation.
What Could Support a Move Toward the Target
- Very low valuation: A price-to-sales ratio near 0.15x means the market is assigning minimal value to each dollar of revenue, leaving room for re-rating if results stabilize.
- Tender-offer history: The company has periodically launched tender offers around its annual shareholder meeting, a pattern that has historically drawn buyers and lifted the share price.
- Cost-reduction efforts: Management's cost-cutting and remediation plan, disclosed during the going-concern review, could improve margins and cash generation if executed successfully.
- Strong recovery off the low: The stock has already rebounded sharply from its 52-week low near $3.80, indicating renewed speculative interest.
What Could Prevent the Target From Being Reached
- Declining revenue: Multi-year sales erosion in a competitive wellness and network-marketing industry weighs on the growth case.
- Persistent losses: Negative EPS and weak profitability metrics limit fundamental support for a higher valuation.
- Going-concern risk: The auditor's review raises legitimate questions about the company's ability to sustain operations, which could cap investor enthusiasm.
- Thin liquidity and wide swings: With a very small float and low average volume, the stock is prone to sharp, sentiment-driven moves in both directions.
Technical Levels and Market Structure
The most relevant technical reference point is the 52-week high near $9.97, which sits just below the $10 psychological level and represents a key resistance zone. A decisive move above that area would require sustained buying in a stock with very limited liquidity. On the downside, the prior trading range between roughly $4 and $6.50, seen earlier in the period, marks the main support region below the current price.
Time Horizon and What Investors Should Monitor
Because there is no meaningful analyst consensus, no standardized research horizon applies to the $10 objective. The most important items to watch are the company's quarterly revenue and EPS trends, any update on the going-concern review and cost-reduction plan, and announcements around the annual meeting window, where tender offers have historically been considered. Investors should also monitor whether any new analyst coverage or ratings emerge, given how little independent research currently exists.
Using AI Daily Buy/Sell Signals for Low-Coverage Names
For traders looking to track changing conditions in stocks and ETFs, Tickeron's AI Daily Buy/Sell Signals provide a data-driven complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of securities and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. This can help traders discover new opportunities, keep an eye on existing positions, and identify shifting trends more efficiently than manual scanning alone. For a low-coverage name like MTEX, such tools can offer an additional, objective lens on momentum and risk. I find this approach particularly useful when digging into thinly followed micro-caps where traditional research is scarce.
Final Assessment
Whether Mannatech can reach $10 depends less on analyst conviction — which is essentially absent — and more on company-specific catalysts such as stabilizing revenue, resolving the going-concern review, or another tender offer. The roughly 16.8% move required is substantial, and the stock's very low valuation and recovery off its low are offset by declining sales, ongoing losses, and balance-sheet uncertainty. With no reliable analyst consensus to lean on, the $10 level should be read as a technical and psychological milestone from public discussion rather than a forecast, and investors should monitor fundamentals closely before drawing any conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MTEX in upward trend: price rose above 50-day moving average on October 19, 2026
MTEX moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 49 of 55 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MTEX as a result. In 92 of 117 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +11.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTEX advanced for three days, in 137 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 105 of 122 cases where MTEX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 52 cases where MTEX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for MTEX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 47 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MTEX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTEX's P/B Ratio (-3.149) is slightly lower than the industry average of (3.045). P/E Ratio (-2.074) is within average values for comparable stocks, (55.291). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (0.741). MTEX's Dividend Yield (0.099) is considerably higher than the industry average of (0.015). P/S Ratio (0.139) is also within normal values, averaging (0.357).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MTEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of nutritional supplements, topical products, and weight-management products
Industry FoodDistributors
Advertisement